The Japanese researcher Prof. Shimon Sakaguchi of Osaka University was recently honoured with the prestigious Paul Ehrlich Award for his discovery of regulatory T cells, which he worked on in the 1990s. The regulatory T cells are a subgroup of T cells, responsible for stopping and controlling the activation of the immune system. This way they prevent the development of autoimmune diseases, but can also hinder the necessary immune reaction against tumour cells. This is why we take them in consideration during the IOZK Immunotherapy.
Prof. Dr. Volker Schirrmacher and Stefaan van Gool, MD PHD, have already published several scientific papers on this topic:
Nummer D, Suri-Payer E, Schmitz-Winnenthal H, Bonertz A, Galindo L, Antolovich D, Koch M, Büchler M, Weitz J, Schirrmacher V, Beckhove P: Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst. 2007 Aug 1;99(15):1188-99.
Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW: DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol. 2009 Oct;11(5):529-42.
Verbinnen B, Billiau AD, Vermeiren J, Galicia G, Bullens DM, Boon L, Cadot P, Hens G, Dewolf-Peeters C, Van Gool SW, Ceuppens JL: Contribution of regulatory T cells and effector T cell deletion in tolerance induction by costimulation blockade. J Immunol. 2008 Jul 15;181(2):1034-42.